Heliobacter Pylori Eradication Reduces Risk of Gastric Cancer for Over 10 Years
the Cancer Therapy Advisor take:
According to a recent study published in the Journal of Gastroenterology, eradicating the bacteria Heliobacter pylori in patients with peptic ulcer disease reduces the risk for developing gastric cancer for more than 10 years, but that gastric cancer can develop after that time period.
These results are part of a follow-up prospective cohort study in which patients were followed for as long as 17.4 years. Researchers previously reported that eradicating Heliobacter pylori in patients with peptic ulcer disease decreases the risk for developing stomach cancer to about 33% after an average follow-up of 3.4 years.
For the study, 1,222 patients with peptic ulcer disease who received over 1 year of follow-up after being treated for H. pylori received an annual endoscopy for an average of 9.9 years and for as long as 17.4 years.
Of the 1,222 patients, 1,030 were successfully cured of H. pylori and gastric cancer occurred in 21 of those patients. Of the 192 who were not successfully cured of H. pylori, 9 developed the disease. Statistical analyses show that the risk for developing gastric cancer was 0.21%/year and 0.45%/year in the eradication-success group and failure group, respectively.
Of those that developed gastric cancer in the eradication-success group, the longest interval between eradication and cancer occurrence was 14.5 years.
Eradicating Heliobacter pylori reduces risk for developing gastric cancer for more than 10 years.
The authors previously reported that eradication of Helicobacter pylori in the cohort of patients with peptic ulcer disease reduced their risk of developing gastric cancer to approximately one–third after a mean follow-up period of 3.4 years (up to 8.6 years) and now followed these patients for a longer period.
A prophylactic effect for gastric cancer persists for more than 10 years after H. pylori eradication therapy, but they should be aware that cancer can develop even after that interval.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma